169 related articles for article (PubMed ID: 32768356)
1. Active Surveillance for Intermediate-Risk Prostate Cancer: Systematic Review and Meta-analysis of Current Protocols and Outcomes.
Enikeev D; Morozov A; Taratkin M; Barret E; Kozlov V; Singla N; Rivas JG; Podoinitsin A; Margulis V; Glybochko P
Clin Genitourin Cancer; 2020 Dec; 18(6):e739-e753. PubMed ID: 32768356
[TBL] [Abstract][Full Text] [Related]
2. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.
Willemse PM; Davis NF; Grivas N; Zattoni F; Lardas M; Briers E; Cumberbatch MG; De Santis M; Dell'Oglio P; Donaldson JF; Fossati N; Gandaglia G; Gillessen S; Grummet JP; Henry AM; Liew M; MacLennan S; Mason MD; Moris L; Plass K; O'Hanlon S; Omar MI; Oprea-Lager DE; Pang KH; Paterson CC; Ploussard G; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; Van den Broeck T; van der Kwast TH; van der Poel HG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TBL
Eur Urol; 2022 Apr; 81(4):337-346. PubMed ID: 34980492
[TBL] [Abstract][Full Text] [Related]
4. Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and Metaregression.
Baboudjian M; Breda A; Rajwa P; Gallioli A; Gondran-Tellier B; Sanguedolce F; Verri P; Diana P; Territo A; Bastide C; Spratt DE; Loeb S; Tosoian JJ; Leapman MS; Palou J; Ploussard G
Eur Urol Oncol; 2022 Dec; 5(6):617-627. PubMed ID: 35934625
[TBL] [Abstract][Full Text] [Related]
5. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract][Full Text] [Related]
6. Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.
Musunuru HB; Yamamoto T; Klotz L; Ghanem G; Mamedov A; Sethukavalan P; Jethava V; Jain S; Zhang L; Vesprini D; Loblaw A
J Urol; 2016 Dec; 196(6):1651-1658. PubMed ID: 27569437
[TBL] [Abstract][Full Text] [Related]
7. Patient and Context Factors in the Adoption of Active Surveillance for Low-Risk Prostate Cancer.
Ciccone G; De Luca S; Oderda M; Munoz F; Krengli M; Allis S; Baima CG; Barale M; Bartoncini S; Beldì D; Bellei L; Bellissimo AR; Bernardi D; Biamino G; Billia M; Borsa R; Cante D; Castelli E; Cattaneo G; Centrella D; Collura D; Coppola P; Dalmasso E; Di Stasio A; Fasolis G; Fiorio M; Garibaldi E; Girelli G; Griffa D; Guercio S; Migliari R; Molinaro L; Montefiore F; Montefusco G; Moroni M; Muto G; Ponti di Sant'Angelo F; Ruggiero L; Ruo Redda MG; Serao A; Squeo MS; Stancati S; Surleti D; Varvello F; Volpe A; Zaramella S; Zarrelli G; Zitella A; Bollito E; Gontero P; Porpiglia F; Galassi C; Bertetto O;
JAMA Netw Open; 2023 Oct; 6(10):e2338039. PubMed ID: 37847502
[TBL] [Abstract][Full Text] [Related]
8. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
[TBL] [Abstract][Full Text] [Related]
9. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
10. Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance.
Nyame YA; Almassi N; Haywood SC; Greene DJ; Ganesan V; Dai C; Zabell J; Reichard C; Arora H; Zampini A; Crane A; Hettel D; Elshafei A; Fareed K; Stein RJ; Berglund RK; Gong M; Jones JS; Klein EA; Stephenson AJ
J Urol; 2017 Sep; 198(3):591-599. PubMed ID: 28347770
[TBL] [Abstract][Full Text] [Related]
11. Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach.
Timilshina N; Alibhai SMH; Tomlinson G; Sander B; Cheung DC; Finelli A
J Urol; 2023 Mar; 209(3):540-548. PubMed ID: 36475730
[TBL] [Abstract][Full Text] [Related]
12. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
[TBL] [Abstract][Full Text] [Related]
13. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review.
van den Bergh RC; Ahmed HU; Bangma CH; Cooperberg MR; Villers A; Parker CC
Eur Urol; 2014 Jun; 65(6):1023-31. PubMed ID: 24491309
[TBL] [Abstract][Full Text] [Related]
14. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study.
Stavrinides V; Giganti F; Trock B; Punwani S; Allen C; Kirkham A; Freeman A; Haider A; Ball R; McCartan N; Whitaker H; Orczyk C; Emberton M; Moore CM
Eur Urol; 2020 Sep; 78(3):443-451. PubMed ID: 32360049
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
[TBL] [Abstract][Full Text] [Related]
16. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
18. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
Tosoian JJ; Mamawala M; Epstein JI; Landis P; Macura KJ; Simopoulos DN; Carter HB; Gorin MA
Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
[TBL] [Abstract][Full Text] [Related]
19. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
[TBL] [Abstract][Full Text] [Related]
20. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
